Safety and Efficacy maintenance study of quetiapine SR to treat GAD patients. - PLATINUM
Study identifier:D1448C00012
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Multi-centre,Double-blind,Randomised-Withdrawal,Parallel-group, Placebo-controlled Phase III Study of the Efficacy and Safety of Quetiapine SR as Monotherapy in the Maintenance Treatment of Patients with GAD Following an Open-Label Stabilisation Period
Medical condition
Anxiety Disorders
Phase
Phase 3
Healthy volunteers
No
Study drug
Quetiapine SR
Sex
All
Actual Enrollment
575
Study type
Interventional
Age
18 Years - 65 Years
Date
Study Start Date: 01 Mar 2006
Primary Completion Date: -
Study Completion Date: 01 Aug 2007
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
Martin Brecher
AstraZeneca
